Aescap

Aescap Venture is an investment firm based in Amsterdam, founded in 2006. The company focuses on investing in biotech and life sciences companies in Europe and the United States. Aescap aims to identify and support innovative firms within the life sciences sector, leveraging its expertise to foster growth and development in this field.

Michiel de Haa

Fund Advisor, General Partner and Co-Founder

Michiel A. de Haan

General partner

Patrick Krol

Portfolio Manager

Michaël Mellink

Investment Partner

Dinko Valerio

Co-Founder

28 past transactions

F-Star Therapeutics

Post in 2020
F-star Therapeutics, Inc., a clinical-stage biopharmaceutical company develops tetravalent bispecific antibodies for cancer therapy. Its medicines used in immuno-oncology treatments. The company plans for the initiation of a Phase I, open label, first-in-human clinical study of FS222, a bispecific antibody targeting CD137 (4-1BB) and PD-L1. The company is based in Cambridge, the United Kingdom.

Orphazyme

Post in 2017
Orphazyme develops innovative new therapies for the treatment of a family of serious genetic disordes called lysosomal storage diseases, and is based on discoveries emerging from the academic laboratory of its scientific founders: Professor Marja Jäättela and Thomas Kirkegaard Jensen from the Danish Cancer Society (Kræftens Bekæmpelse). Orphazyme is based in Copenhagen and has established collaborations with top-tier academic institutions in Europe and USA.

Orphazyme

Venture Round in 2017
Orphazyme develops innovative new therapies for the treatment of a family of serious genetic disordes called lysosomal storage diseases, and is based on discoveries emerging from the academic laboratory of its scientific founders: Professor Marja Jäättela and Thomas Kirkegaard Jensen from the Danish Cancer Society (Kræftens Bekæmpelse). Orphazyme is based in Copenhagen and has established collaborations with top-tier academic institutions in Europe and USA.

i-Optics

Venture Round in 2015
i-Optics B.V. is a medical device company based in The Hague, Netherlands, specializing in the development and distribution of optical devices for eye diagnosis. Founded in 2003, the company offers innovative solutions such as Cassini, a corneal shape analyzer that utilizes color LED technology to measure the true axis and magnitude of corneal astigmatism, which is crucial for premium intraocular lens (IOL) planning. Additionally, i-Optics provides EasyScan, a retinal imaging system that employs scanning laser ophthalmoscopy (SLO) technology to diagnose various retinal diseases, including diabetic retinopathy, age-related macular degeneration, and glaucoma, without the need for pupil dilation. Through its advanced, user-friendly products, i-Optics aims to enhance the quality of eye care for healthcare providers and their patients worldwide.

Orphazyme

Series B in 2015
Orphazyme develops innovative new therapies for the treatment of a family of serious genetic disordes called lysosomal storage diseases, and is based on discoveries emerging from the academic laboratory of its scientific founders: Professor Marja Jäättela and Thomas Kirkegaard Jensen from the Danish Cancer Society (Kræftens Bekæmpelse). Orphazyme is based in Copenhagen and has established collaborations with top-tier academic institutions in Europe and USA.

Avantium

Series G in 2014
Avantium is a technology company based in Amsterdam, specializing in advanced high-throughput research and development for the energy, chemicals, and pharmaceutical sectors. It employs proprietary technology that accelerates and reduces the costs associated with developing new products and processes. Avantium's innovative approach to experiment design and data analysis enhances its success rate in delivering effective solutions. The company has successfully collaborated with over 70 global clients, showcasing the commercial viability of its services. Avantium focuses on two primary areas: developing biofuels and bio-based chemicals, as well as new crystal forms of patented drugs. Its business model includes a strong emphasis on expanding its patent portfolio and establishing partnerships that add value. Additionally, Avantium operates through segments such as R&D Solutions, Renewable Chemistries, and Renewable Polymers, with the R&D Solutions segment generating the majority of its revenue. The company is supported by a team of experts in various fields, including catalysis, organic chemistry, and software development, who work closely with partner organizations to drive innovation in sustainable chemistry.

F-Star Therapeutics

Series A in 2013
F-star Therapeutics, Inc., a clinical-stage biopharmaceutical company develops tetravalent bispecific antibodies for cancer therapy. Its medicines used in immuno-oncology treatments. The company plans for the initiation of a Phase I, open label, first-in-human clinical study of FS222, a bispecific antibody targeting CD137 (4-1BB) and PD-L1. The company is based in Cambridge, the United Kingdom.

Orphazyme

Series A in 2011
Orphazyme develops innovative new therapies for the treatment of a family of serious genetic disordes called lysosomal storage diseases, and is based on discoveries emerging from the academic laboratory of its scientific founders: Professor Marja Jäättela and Thomas Kirkegaard Jensen from the Danish Cancer Society (Kræftens Bekæmpelse). Orphazyme is based in Copenhagen and has established collaborations with top-tier academic institutions in Europe and USA.

Avantium

Venture Round in 2011
Avantium is a technology company based in Amsterdam, specializing in advanced high-throughput research and development for the energy, chemicals, and pharmaceutical sectors. It employs proprietary technology that accelerates and reduces the costs associated with developing new products and processes. Avantium's innovative approach to experiment design and data analysis enhances its success rate in delivering effective solutions. The company has successfully collaborated with over 70 global clients, showcasing the commercial viability of its services. Avantium focuses on two primary areas: developing biofuels and bio-based chemicals, as well as new crystal forms of patented drugs. Its business model includes a strong emphasis on expanding its patent portfolio and establishing partnerships that add value. Additionally, Avantium operates through segments such as R&D Solutions, Renewable Chemistries, and Renewable Polymers, with the R&D Solutions segment generating the majority of its revenue. The company is supported by a team of experts in various fields, including catalysis, organic chemistry, and software development, who work closely with partner organizations to drive innovation in sustainable chemistry.

F-Star Therapeutics

Venture Round in 2011
F-star Therapeutics, Inc., a clinical-stage biopharmaceutical company develops tetravalent bispecific antibodies for cancer therapy. Its medicines used in immuno-oncology treatments. The company plans for the initiation of a Phase I, open label, first-in-human clinical study of FS222, a bispecific antibody targeting CD137 (4-1BB) and PD-L1. The company is based in Cambridge, the United Kingdom.

to-BBB

Series B in 2011
to-BBB is a clinical stage biotechnology company developing novel treatments for devastating brain disorders, such as brain cancer and neuroinflammatory diseases. The Company combines existing drugs with to-BBB’s proprietary G-Technology® for enhanced drug delivery across the blood-brain barrier. to-BBB currently has two products in clinical trials: its lead product 2B3-101 is in a Phase IIa trial in Europe and the US for the treatment of primary brain tumors as well as brain metastases; the second product 2B3-201 for MS relapses and other neuroinflammatory diseases is completing a Phase I clinical study. to-BBB is headquartered in the Netherlands at the Leiden Bio Science Park and established a fully owned subsidiary, to-BBB Taiwan Ltd., in Taipei, Taiwan. Investors in to-BBB include Aescap Venture, Antea Participaties, Jonghoud International and the Industrial Bank of Taiwan Management Corporation (IBTM).

i-Optics

Series C in 2010
i-Optics B.V. is a medical device company based in The Hague, Netherlands, specializing in the development and distribution of optical devices for eye diagnosis. Founded in 2003, the company offers innovative solutions such as Cassini, a corneal shape analyzer that utilizes color LED technology to measure the true axis and magnitude of corneal astigmatism, which is crucial for premium intraocular lens (IOL) planning. Additionally, i-Optics provides EasyScan, a retinal imaging system that employs scanning laser ophthalmoscopy (SLO) technology to diagnose various retinal diseases, including diabetic retinopathy, age-related macular degeneration, and glaucoma, without the need for pupil dilation. Through its advanced, user-friendly products, i-Optics aims to enhance the quality of eye care for healthcare providers and their patients worldwide.

Biocartis

Series B in 2010
Biocartis Group NV is a molecular diagnostics company that specializes in developing diagnostic solutions with a strong emphasis on oncology. The company’s proprietary Idylla platform utilizes real-time polymerase chain reaction technology to deliver critical molecular information that aids in treatment selection and monitoring. Biocartis offers a range of diagnostic tests, including solid biopsy tests for mutations such as BRAF, KRAS, and EGFR, as well as plasma liquid biopsy tests for ctKRAS and ctNRAS. In addition to its diagnostic offerings, the company collaborates with major pharmaceutical firms like AstraZeneca and Bristol-Myers Squibb to create companion diagnostics that enhance treatment efficacy in cancer care. Founded in 2007, Biocartis is headquartered in Mechelen, Belgium, and strives to improve personalized medical treatments through its innovative diagnostic systems.

Aquapharm Biodiscovery

Series C in 2010
Aquapharm is an innovative drug discovery company focussed on developing new products founded on the chemical diversity of marine micro-organisms. Their core focus is the development of novel pharmaceutical compounds leading to the development of novel antibiotics, targeting both Gram negative and Gram positive infections. In addition, Aquapharm's development pipeline is also fed by an active discovery portfolio of anti-oxidants, anti-inflammatories and novel biocatalysts.

Affectis Pharmaceuticals

Series D in 2010
Affectis Pharmaceuticals is a company focused on the development of innovative drugs aimed at treating neurodegenerative and neuroinflammatory diseases. By leveraging advanced research and development techniques, Affectis seeks to address significant unmet medical needs in these challenging areas of healthcare. The company is dedicated to creating effective therapeutic solutions that can improve the quality of life for patients affected by these conditions.

F-Star Therapeutics

Series A in 2010
F-star Therapeutics, Inc., a clinical-stage biopharmaceutical company develops tetravalent bispecific antibodies for cancer therapy. Its medicines used in immuno-oncology treatments. The company plans for the initiation of a Phase I, open label, first-in-human clinical study of FS222, a bispecific antibody targeting CD137 (4-1BB) and PD-L1. The company is based in Cambridge, the United Kingdom.

Biocartis

Series A in 2009
Biocartis Group NV is a molecular diagnostics company that specializes in developing diagnostic solutions with a strong emphasis on oncology. The company’s proprietary Idylla platform utilizes real-time polymerase chain reaction technology to deliver critical molecular information that aids in treatment selection and monitoring. Biocartis offers a range of diagnostic tests, including solid biopsy tests for mutations such as BRAF, KRAS, and EGFR, as well as plasma liquid biopsy tests for ctKRAS and ctNRAS. In addition to its diagnostic offerings, the company collaborates with major pharmaceutical firms like AstraZeneca and Bristol-Myers Squibb to create companion diagnostics that enhance treatment efficacy in cancer care. Founded in 2007, Biocartis is headquartered in Mechelen, Belgium, and strives to improve personalized medical treatments through its innovative diagnostic systems.
EOS is a biopharmaceutical company committed to the development of novel medicines for the treatment of cancer.EOS S.p.A. was founded in June 2006 by Silvano Spinelli, Gabriella Camboni, and Ennio Cavalletti along with Jacques Theurillat. Company’s operations were seed and further financed by founders and by Sofinnova Partners since its inception. EOS is a privately held organization headquartered in Via Monte di Pietà, 1/A, Milano, Italy.

ActoGeniX

Private Equity Round in 2009
ActoGeniX is a biopharmaceutical company based in Zwijnaarde, Belgium, founded in 2006 by Bernard Coulie and Mark Vaeck. The company specializes in the development and commercialization of innovative biological drugs, utilizing a proprietary technology platform that leverages living non-pathogenic microorganisms for oral delivery of biopharmaceuticals. ActoGeniX aims to address unmet medical needs in gastrointestinal, immunological, and metabolic diseases, contributing to advancements in therapeutic options within these fields.

Avantium

Venture Round in 2008
Avantium is a technology company based in Amsterdam, specializing in advanced high-throughput research and development for the energy, chemicals, and pharmaceutical sectors. It employs proprietary technology that accelerates and reduces the costs associated with developing new products and processes. Avantium's innovative approach to experiment design and data analysis enhances its success rate in delivering effective solutions. The company has successfully collaborated with over 70 global clients, showcasing the commercial viability of its services. Avantium focuses on two primary areas: developing biofuels and bio-based chemicals, as well as new crystal forms of patented drugs. Its business model includes a strong emphasis on expanding its patent portfolio and establishing partnerships that add value. Additionally, Avantium operates through segments such as R&D Solutions, Renewable Chemistries, and Renewable Polymers, with the R&D Solutions segment generating the majority of its revenue. The company is supported by a team of experts in various fields, including catalysis, organic chemistry, and software development, who work closely with partner organizations to drive innovation in sustainable chemistry.

Vivendy Therapeutics

Series B in 2008
Vivendy Therapeutics Ltd. has developed a specific recombinant human N-acetylgalactosamine-6-sulfatase (rhGALNS) that is specifically modified to improve enzyme activity - enhancing the efficacy of the therapy in MPS IVA significantly

ProtAffin Biotechnologie

Series A in 2008
ProtAffin is a biotechnology company in Austria developing a novel class of biopharmaceutical products that act by targeting cell-surface glycan structures. ProtAffin's products are first-in-class engineered versions of human proteins which bind to cell surface glycans (sugars) to affect their biological activity. Activated versions of specific cell surface glycans underlie inflammatory processes in several diseases including rheumatoid arthritis, chronic obstructive pulmonary disorder, Crohn's disease and cancer and represent a rich and relatively under-investigated class of potential drug targets for the pharmaceutical and biotechnology industries. Protaffin's approach is entirely innovative and opens up glycans as druggable targets through the use of its CellJammer® discovery platform.

F-Star Therapeutics

Series A in 2007
F-star Therapeutics, Inc., a clinical-stage biopharmaceutical company develops tetravalent bispecific antibodies for cancer therapy. Its medicines used in immuno-oncology treatments. The company plans for the initiation of a Phase I, open label, first-in-human clinical study of FS222, a bispecific antibody targeting CD137 (4-1BB) and PD-L1. The company is based in Cambridge, the United Kingdom.

Aquapharm Biodiscovery

Series B in 2007
Aquapharm is an innovative drug discovery company focussed on developing new products founded on the chemical diversity of marine micro-organisms. Their core focus is the development of novel pharmaceutical compounds leading to the development of novel antibiotics, targeting both Gram negative and Gram positive infections. In addition, Aquapharm's development pipeline is also fed by an active discovery portfolio of anti-oxidants, anti-inflammatories and novel biocatalysts.

to-BBB

Series A in 2007
to-BBB is a clinical stage biotechnology company developing novel treatments for devastating brain disorders, such as brain cancer and neuroinflammatory diseases. The Company combines existing drugs with to-BBB’s proprietary G-Technology® for enhanced drug delivery across the blood-brain barrier. to-BBB currently has two products in clinical trials: its lead product 2B3-101 is in a Phase IIa trial in Europe and the US for the treatment of primary brain tumors as well as brain metastases; the second product 2B3-201 for MS relapses and other neuroinflammatory diseases is completing a Phase I clinical study. to-BBB is headquartered in the Netherlands at the Leiden Bio Science Park and established a fully owned subsidiary, to-BBB Taiwan Ltd., in Taipei, Taiwan. Investors in to-BBB include Aescap Venture, Antea Participaties, Jonghoud International and the Industrial Bank of Taiwan Management Corporation (IBTM).

ProtAffin Biotechnologie

Series A in 2007
ProtAffin is a biotechnology company in Austria developing a novel class of biopharmaceutical products that act by targeting cell-surface glycan structures. ProtAffin's products are first-in-class engineered versions of human proteins which bind to cell surface glycans (sugars) to affect their biological activity. Activated versions of specific cell surface glycans underlie inflammatory processes in several diseases including rheumatoid arthritis, chronic obstructive pulmonary disorder, Crohn's disease and cancer and represent a rich and relatively under-investigated class of potential drug targets for the pharmaceutical and biotechnology industries. Protaffin's approach is entirely innovative and opens up glycans as druggable targets through the use of its CellJammer® discovery platform.

ActoGeniX

Venture Round in 2007
ActoGeniX is a biopharmaceutical company based in Zwijnaarde, Belgium, founded in 2006 by Bernard Coulie and Mark Vaeck. The company specializes in the development and commercialization of innovative biological drugs, utilizing a proprietary technology platform that leverages living non-pathogenic microorganisms for oral delivery of biopharmaceuticals. ActoGeniX aims to address unmet medical needs in gastrointestinal, immunological, and metabolic diseases, contributing to advancements in therapeutic options within these fields.

Affectis Pharmaceuticals

Series C in 2006
Affectis Pharmaceuticals is a company focused on the development of innovative drugs aimed at treating neurodegenerative and neuroinflammatory diseases. By leveraging advanced research and development techniques, Affectis seeks to address significant unmet medical needs in these challenging areas of healthcare. The company is dedicated to creating effective therapeutic solutions that can improve the quality of life for patients affected by these conditions.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.